Can some patients with mid-rectal cancer skip pre-surgery treatment?
Part of Cancer, Digestive system clinical trials.
This study is looking at whether people with mid-rectal cancer can skip chemotherapy and radiation before surgery. The goal is to see if surgery alone is enough for certain patients, to avoid unnecessary side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with rectal cancer.
- Your tumor is located in the middle part of the rectum, about 2.5 to 5 inches from the anal verge.
- Your tumor is at a stage that has not spread to nearby organs (stage II or III).
- Your MRI shows no signs of cancer in the nearby lymph nodes or blood vessels.
- You have not had radiation therapy to the pelvis before.
- You do not have inflammatory bowel disease, polyposis syndromes, or a family history of certain colon cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two approaches for low-risk locally advanced rectal cancer: going straight to surgery (TME) versus receiving chemotherapy before surgery. The goal is to see if upfront surgery works just as well, sparing patients from chemotherapy side effects.
This trial tests whether a full course of chemotherapy and radiation before any surgery (called total neoadjuvant therapy) can help you avoid surgery and preserve your rectum. It is for people with a specific early stage of rectal cancer that has not spread.
This study tests a new combination of treatment before surgery for high-risk rectal cancer. It combines a shorter course of radiation with chemotherapy and immunotherapy (which helps your immune system fight cancer) to see if it shrinks the tumor and improves outcomes.
This trial tests how well a precise surgery removes the remaining rectal cancer after you have had radiation and chemotherapy. It is for people whose tumor has shrunk a lot but is still there, and the tumor is very low in the rectum.
This Phase 2 study tests a “total neoadjuvant” approach, meaning you receive cancer treatment before surgery, to improve safety and effectiveness for rectal cancer. It may help by shrinking the tumor and planning a more effective operation, while researchers carefully track side effects.
This trial tests whether people with early- to intermediate-stage low rectal cancer can avoid surgery if their tumor responds well to a full course of chemotherapy and radiation. It starts with brief chemotherapy, then adjusts treatment based on how much the tumor shrinks.
Hear when a new Rectal Cancer Stage II trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.